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Abstract: TNFα receptors, TNF-R1 and TNF-R2, mediate the biological activities of the 
multifunctional cytokine, tumor necrosis factor alpha, TNFα. These receptors have a central 
role in human pregnancy. Although each receptor induces distinct intracellular signals, they 
also have co-operative and overlapping effects. The membrane bound TNF-R1 carries out most 
of the pro-inflammatory activities of TNFα, especially those that are rapid, while TNF-R2 is 
involved in the late long-term effects of this cytokine. The soluble forms of these receptors 
can bind to TNFα, neutralizing its effects. In normal human pregnancy, TNFα receptors are 
present in the maternal circulation, placenta, amniotic fluid, and coelomic cavity. Changes in 
TNFα and its receptors are associated with adverse pregnancy outcomes, including miscarriage, 
preterm labor and preeclampsia. Advances in anti-TNFα therapy may have potential use in the 
management of complicated pregnancies.
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Introduction
The role of maternal leucocytes and other immune factors such as cytokines in the 
trophoblast-decidual interaction remains unclear. There are two major subsets of CD4+ 
T-helper mediated responses, T-helper Th1 and Th2,1 which act via different patterns of 
cytokine production. Th1 cells secrete tumor necrosis factor (TNF) α and β, interferon 
gamma (IFNγ) and interleukin (IL)-2. This cell-mediated immune response, also known 
as Type 1 response, involves activation of macrophages and cell-mediated reactions 
involved in resisting infections due to intracellular pathogens, and cytotoxic and 
delayed-type hypersensitivity reactions. Th2 type cytokines include IL-4, IL-5, IL-6, 
IL-10, and IL-13, which are associated with strong antibody responses to infections 
with extracellular organisms (Type 2 or humoral reactions).2 There is evidence that 
cytokines are pivotal in the reproductive immune response.3–6 Normal pregnancy is 
now considered to be a state of controlled mild maternal systemic inflammation, where 
circulating levels of pro-inflammatory cytokines, including TNFα, are raised compared 
to the non-pregnant state, in a way similar to what happens during sepsis.7 These 
pro-inflammatory cytokines are produced by monocytes and also by trophoblasts.8,9 It 
has been hypothesized that during normal pregnancy, there is a subtle immunological 
shift to the Th2-type cytokine responses that would suppress the potential harmful 
effects of the cell-mediated (Th1-type) immune system.3 Imbalance in the Th1/Th2 
cytokine response with an increase in Th 1 cytokines is associated with adverse 
pregnancy outcome.5
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Structure and bioactivities  
of TNFα receptors
TNFα is a potent, multifunctional cytokine in autocrine 
and paracrine processes central to reproduction. These 
processes include gamete, follicle and luteal development, 
steroidogenesis, uterine cyclicity, placental differentiation, 
development of the embryo, and parturition.10 The biological 
activities of TNFα are mediated via two different TNFα 
receptors (TNF-Rs): TNF-R1 (also known as p55/p60, Type 
I, b, TNF-R55, TNF-Rβ or CD120a) with a molecular mass 
of 55–60 kDa; and TNF-R2 (or p75/p80, Type II, a, TNF-R75, 
TNF-Rα or CD120b), weighing 75–80 kDa11,12 (Table 1).
The differential expression of the two TNF-Rs is regulated 
by female sex steroid hormones. These two receptors consist 
of a homologous extracellular, cysteine-rich transmembrane 
domain, but their intracellular domains are entirely differ-
ent, and each receptor is independently regulated. Although 
each receptor induces distinct intracellular signals, they 
also have co-operative and overlapping effects. In cells 
responding to TNFα via the TNF-R1, the extracellular part 
of TNF-R2 captures TNFα, even at low concentrations, and 
delivers it to TNF-R1, resulting in an enhanced response to 
TNFα.13
Depending on cell type and activation status, the number 
of receptors per cell ranges from 100 to 10,000 copies.14,15 The 
TNF-R1 is found on most tissues, and seems to be the main 
mediator of TNFα signaling, leading to pro-inflammatory 
and programmed cell death pathways, and is therefore 
associated with cytotoxicity. TNF-R1 carries out most of 
the activities of TNFα, especially those that are rapid, while 
TNF-R2 is involved in the late long-term effects of this 
cytokine. TNF-R2 is more prevalent in immune cells11,16 
and is primarily associated with lymphocyte proliferation. 
While TNF-R2 may induce apoptosis,17 it can also enhance 
tissue repair and angiogenesis, thus promoting cell survival.18 
Other biological activities of TNF-Rs include gene  induction 
in endothelial cells, inducing cytokine production, and 
activation of nuclear factor kappa-light-chain-enhancer of 
B cells.15,19,20
Both receptors can have their extracellular domains 
cleaved from the membrane, thus forming soluble TNF-Rs. 
The soluble TNF-Rs are present in the serum and urine and 
have been shown to protect against the harmful effects of 
excessive TNFα by neutralizing this cytokine.21 The soluble 
form of TNF-R2 is cleaved by proteolysis through the metal-
loproteinase TNFα converting enzyme (TACE, also known as 
ADAM17).22,23 Soluble TNF-R2 is involved in the inactivation 
of TNFα in the circulation by the formation of high affinity 
complexes. This subsequently reduces the binding of TNFα 
to target cell membrane receptors and downregulates the 
response to TNFα.24 The proteolytic enzyme that releases 
soluble TNF-R1 is still unknown.9 Lack of soluble TNF-R1 
leads to autosomal dominant inherited auto-inflammatory 
syndromes.25
TNFα and its receptors during  
the normal first trimester
In situ hybridization studies and immunohistochemical 
analyses have shown that in non-pregnant women, the expres-
sion of TNFα protein in the endometrial glands is negligible in 
the early proliferative phase, then increases and peaks during 
the late proliferative phase. In the secretory phase, TNFα pro-
tein expression remains high, but slightly less than in the late 
proliferative phase.26,27 Both TNF-Rs follow a similar pattern, 
with the highest expression in the late secretory phase.28
Following decidualisation, TNFα mRNA has been 
shown to be present in macrophages,29 T-cells,30 uterine 
NK cells, endothelial cells,31 and decidual stromal cells 
Table 1 Comparison between TNF-R1 and TNF-R2
TNF-R1 TNF-R2
Other names p55/p60, Type I, b, TNF-R55, TNF-Rβ or CD120a p75/p80, Type II, a, TNF-R75, TNF-Rα or CD120b
Molecular weight 55 kDa 75–80 kDa
Structure Contains the DD Does not contain the DD
expressed cell types Most tissues, including the proliferating cytotrophoblast  
of the cell islands and cell columns, the evT invading  
the decidual tissue, and villous stromal cells
Immune cells
Functions The main mediator of TNFα signalling, leading  
to proinflammatory and programmed cell death pathways,  
and cytotoxicity; carries out most of the activities  
of TNFα, especially those which are rapid
Primarily associated with lymphocyte proliferation,  
may induce apoptosis, can enhance tissue repair  
and angiogenesis; soluble TNF-R2 is involved in the 
inactivation of TNFα in the circulation
Signaling pathways Interacts indirectly with TRAF2 via TRADD Interacts directly with TRAF2
Abbreviations: DD, death domain; evT, extravillous trophoblasts; TNFα, tumor necrosis factor alpha; TRADD, TNF-α receptor-associated death domain;  TRAF2, TNF-
receptor associated factor 2.
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in vitro.32,33 Other studies have also shown that various 
decidual cell types express TNF-Rs.9 During normal human 
pregnancy, TNFα gene products have been detected in 
amniotic fluid34–38 and soluble TNF-Rs have been detected 
in first trimester coelomic fluid.39 Since pro-inflammatory 
cytokines do not cross normal term placenta,40 TNFα 
and its receptors are probably produced from within the 
gestational sac from a very early stage in pregnancy. 
TNFα gene products have been detected in placental 
supernatants.41,42
During the first trimester, all cell types of trophoblastic 
lineage express TNFα mRNA. These cell types include villous 
and proliferating cytotrophoblasts, syncytiotrophoblasts, and 
the extravillous trophoblasts (EVT) invading the uterine 
wall.43,44 Messenger RNA and protein are found in both fully 
differentiated syncytiotrophoblasts26,45 and proliferating EVT 
cells44 during early human gestation. There is a predominance 
of TNFα in cell columns during invasion especially in 
the EVT as it displaces the endothelial cells of the spiral 
arteries.46,47
TNF-R1 mRNA has been identified in the proliferating 
cytotrophoblast of the cell islands and cell columns, the EVT 
invading the decidual tissue48 and villous stromal cells.49 
There is also a non-uniform distribution of TNF-R1 mRNA 
in villous cytotrophoblasts and syncytiotrophoblasts in the 
first trimester placenta.9 During early gestation, TNF-R1 
protein is expressed widely in villous cytotrophoblasts, EVT 
and cell columns, and trophoblasts.48 As for syncytiotro-
phoblasts, TNF-R1 has been shown to be present during all 
gestational ages.50 Under inflammatory conditions, soluble 
TNF-R1 may protect the trophoblast from the cytotoxic 
effects of TNFα.48
TNF-R2 mRNA has a similar distribution to TNF-R1 
mRNA. TNF-R2 mRNA has been observed in  cultures 
of first trimester trophoblasts, but to a lesser extent than 
TNF-R1.48 It is yet not clear how TNF-R2 is expressed in the 
placenta.9 Studies show that TNF-R2 mRNA is restricted to 
the trophoblast in early pregnancy and, at later stages, shifts 
to placental mesenchymal cells.49
It has been proposed that placental TNFα derived 
from macrophages, possibly modulated by TNFα-TNFRI 
 signaling, facilitates trophoblast differentiation.48,51 TNFα 
at the fetal-maternal interface plays an important role in 
regulating macrophage recruitment by trophoblast cells. It 
has been shown that media conditioned by TNFα-treated 
trophoblast cells significantly enhance the ability of the 
monocyte cell line THP-1 to invade through Matrigel.52 
TNFα might promote proliferation of trophoblast and 
increased human chorionic gonadotrophin secretion by acting 
as an autocrine growth factor via TNF-RI.44
Systemic and placental levels of 
TNFα and its receptors in pregnancy
Prospective longitudinal studies of cytokine expression in the 
circulation during normal pregnancy show that as pregnancy 
progresses, there is an overall decrease in pro-inflammatory 
cytokines such as TNFα and IFNγ, accompanied by an increase 
in the anti-inflammatory cytokines such as IL-10 and IL-6.53,54 
Successful pregnancy requires a delicate balance in Th1/
Th2 cytokines. Plasma levels of TNFα and the neutralizing 
soluble receptor TNF-R2 rise till the second trimester, and then 
decrease.55 This is followed by a shift towards Th2 cytokines 
in the second trimester with an increase in Th2 cytokines till 
term.54 As pregnancy progresses, there is a change in placen-
tal expression of TNFα.26 As for TNF-Rs, TNF-RI mRNA 
and protein are expressed in essentially all types of cells of 
the human placenta, with increasing levels as the pregnancy 
advances to term.39 This suggests that TNFα and its receptors 
may have a specific role in the process of developmental differ-
entiation. Later in pregnancy, TNFα mRNA is more prominent 
in placental macrophages within villous stromal cells than in 
trophoblasts.26,56 In the third trimester, there is less expression 
of TNFα protein in invasive cells, and no expression at all in 
trophoblast giant cells.57 TNFα mRNA and protein are promi-
nent in macrophage-like cells present in term placentas and 
extraplacental membranes.26,29 TNF-R1 mRNA is also present 
in high amounts in the villous stroma and endothelial cells, 
and to a lower extent in the syncytiotrophoblasts of the term 
placenta.49 In cultured third trimester villous cytotrophoblasts, 
cytotoxic effects of TNFα, both alone and in combination 
with IFNγ, have been demonstrated, predominantly induced 
through TNF-R1.58 There are elevated concentrations of 
soluble TNF-Rs in the urine of pregnant women.59 This can be 
explained by the in vitro finding that third trimester trophoblast 
cells rapidly release soluble TNF-R1 and TNF-R2 into the 
culture medium.60 Pregnancy specific glycoproteins derived 
from the placenta increase the secretion of IL-10 and other 
anti-inflammatory cytokines. IL-10 downregulates activity 
of TNFα by inhibiting the release of TNFα, increasing the 
release of soluble TNF-R1 and -R2, and reducing the surface 
expression of both TNF-Rs.61
Total antioxidant activity of amniotic fluid samples from 
asymptomatic mid-trimester women positively correlate with 
soluble TNF-Rs.62 TNFα is important in the initiation and 
amplification of inflammation.63 TNF-Rs may reduce oxidative 
stress due to receptor binding of the inflammatory TNFα.
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Many cell types present in the endometrium, placenta 
and deciduas have been shown to express TNFα and its 
receptors, implying that multiple autocrine and paracrine 
interactions can occur.9 Although there are complementary 
roles for the TNF-receptors, TNF-R1 has been shown to be 
mainly involved in apoptosis in the placenta.58
TNFα and its receptors  
in miscarriage
The balance between pro- and anti-inflammatory cytokines 
is essential for implantation, placental development and 
pregnancy outcome. Changes in the Th1/Th2 balance in the 
feto-maternal interface in favor of Th1 can lead to adverse 
pregnancy outcome, including recurrent spontaneous 
miscarriages.64 Increased Th1 cytokines, including TNFα, 
have been found in women suffering from recurrent 
spontaneous miscarriages.65 It was also demonstrated 
that women with recurrent spontaneous miscarriages had 
reduced levels of soluble TNF-R1 and TNF-R2, which were 
then normalized upon administration of progesterone.66 
Once treated with TNFα inhibitors, this group of women 
had an increase in the rate of live births.67 TNFα is unlikely 
to be the only mediator and, in most cases of miscarriage, 
there are additional triggers.9 Evidence shows that TNFα, 
IFNγ and NK cells cannot induce miscarriage separately, but 
a Th1-NK-macrophage triad may bring about miscarriage, 
which can in turn be suppressed by a Th2 cytokine 
response.3,68
Immunohistochemical studies have shown abundant 
mTNF-R1 expression in the cytotrophoblasts, villous stromal 
cells and vessel endothelial cells derived from placenta from 
women with early spontaneous miscarriage. Over-expression 
of TNF-R1 may mediate TNFα to induce apoptosis in these 
cells, leading to tissue damage in chorionic villi in non-viable 
pregnancies.69 Mice studies are showing that TNFα via 
TNFR1 signaling causes placental pathology leading to fetal 
hypoxia, which can be prevented by TNFα-antagonists.70
TNFα and its receptors in preterm 
labor
Parturition is a complex process, brought about by the right 
combination of signals, following mechanical and endocrine 
stimulation.71 Prematurity occurs in the case of aberrations 
in these signals, together with inflammation, cervical 
abnormalities and/or progesterone resistance. However 
the major mechanism of preterm labor is still unclear. 
Complications of pregnancy have been associated with 
deficient conversion of the uterine spiral arteries, leading to 
abnormal placental perfusion. Placental malperfusion can cause 
oxidative stress,72 induced by an ischemia-reperfusion–type 
insult,73 leading to a rise in pro-inflammatory cytokines and 
anti-angiogenic factors in the maternal circulation.
In the case of late miscarriages and premature labor, TNFα 
and other pro-inflammatory cytokines have been shown to 
stimulate uterine activity and cervical ripening by producing 
prostaglandins74 and cortisol,75 and degrade the extracellu-
lar matrix of chorio-amniotic membranes via MMP-2 and 
MMP-9.76 Oxidative stress and inflammatory cytokines are 
powerful inducers of apoptosis and necrosis. TNFα, together 
with other pro-inflammatory cytokines such as IL-1β, are 
elevated in the amniotic fluid of women with preterm labor 
and/or preterm premature rupture of membranes (PPROM), 
even in the absence of infection.77–79 Pro-inflammatory cytok-
ines can stimulate production of prostaglandins, leading to 
uterine contractions, and upregulation of MMP activation. 
Intra-amniotic inflammation may lead to apoptosis, thus 
weakening fetal membranes and leading to PPROM.80,81
In PPROM, two major apoptotic pathways have been 
implicated. The first is a TNFα receptor-Fas-mediated 
pathway. This initiates signal transduction through 2 docking 
proteins known as TRADD (TNF-α receptor-associated 
death domain) and FADD (Fas-associated death domain), 
which in turn activate pro-caspase-8 to active caspase-8 
(Figure 1). The other apoptotic pathway is p53-mediated, 
initiated by DNA fragmentation with activation of caspase-9. 
Caspase-8 and -9 initiate a cascade of caspase activation, 
followed by sequential activation of caspases 3, 7 and 6, 
leading to proteolysis of structural proteins, proteins of 
homeostasis, and several other target proteins leading to 
apoptosis.82
Lipopolysaccharide (LPS)-induced apoptosis in mac-
rophages has been attributed to the LPS-mediated induction 
of pro-apoptotic TNFα acting back on the cells in an auto-
crine/paracrine  manner.83 LPS triggers TNFα production in 
fetal membranes.84 Elevated endotoxin levels are found in the 
amniotic fluid of women with preterm labor and PPROM.85 
Endotoxin is capable of stimulating prostaglandin production 
in amnion cells, and can initiate preterm labor via the host 
inflammatory response through activation of immunocytes 
and release of inflammatory cytokines.86 Elevated levels of 
TNFα, together with other pro-inflammatory cytokines such 
as IL-1, are found in women with intra-amniotic infection and 
preterm labor, and, in turn, these cytokines stimulate pros-
taglandin synthesis in human tissues.74,85,87 The mRNA from 
TNFα and other pro-inflammatory cytokines is expressed 
in human fetal membranes in response to infection and 
endotoxin stimulation.88 Infection is closely involved in the 
process of preterm birth, partly through the host response via 
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the inflammatory cytokine release, and its effect on starting 
uterine activity.85 TNFα and other pro-inflammatory cytokine 
levels in the amniotic fluid increase towards term and in nor-
mal labor. However, there is an increase in TNFα released 
from the amniochorion, together with other pro-inflammatory 
cytokines in the amniotic fluid of women with preterm labor 
caused by intra-amniotic infection.
Women with preterm labor or PPROM have an elevated 
concentration of IL-689 and TNFα90 in the amniotic fluid, 
compared to women whose preterm labor did not progress 
to preterm delivery.91 Increased TNFα, together with IL-6, 
IL-1 α, IL-1 β, and PGE2 are associated with histologic 
chorioamnionitis among women who delivered within 1 week 
of amniocentesis.90 Ex vivo incubation of whole unprocessed 
amniotic fluid may provide a more accurate indication of the 
cytokine release from amniotic cells, than just measuring the 
soluble components in the unincubated amniotic fluid super-
natant (similar to using whole blood rather than peripheral 
blood mononuclear cells).92
TNFα levels present in amniotic fluid are in the picogram 
per milliliter range.93 TNFα peptide is present only in the 
amnion, but chorionic cells also have mRNA for TNFα.88 
TNFα has been detected in less than half of amniotic fluid 
samples in midtrimester, and even less in cases of preterm 
delivery.62 In Caucasians, midtrimester levels of TNFα and 
soluble TNF-Rs in symptomatic women are not significantly 
different between patients with preterm birth and those who 
proceed to term.36,62 Elevated TNFα concentration in amniotic 
fluid is associated with preterm birth and PPROM,94,93 and 
the bioavailability of TNFα and its receptors influences the 
pathophysiology of these outcomes.95 During an ascending 
infection, the choriodecidua is the first line barrier for patho-
gens such as E.coli, that can cross the amniotic membranes 
and into the amniotic fluid.96 In response to this ascending 
infection, there is abnormal production of TNFα in the 
amnion compartment when the pathogen affects both the 
amniotic membrane and the choriodecidua in vitro (compa-
rable to chorioamnionitis in vivo).97
Apoptosis
MEKK 1 IKK
IKB
NFKB4
PDE 45
TACE3
Soluble TNFα1 Membrane bound TNFα
2
AMP
Caspases
TRAF 2
RIP, FADD
TRADD
In
te
rn
al
is
ed
↑ PKA cAMP
p38
TNFα gene expression
and cell survival
Figure 1 TNF-α signaling and the potential targets for the inhibition of TNF-α-related activities.
Notes: Inhibitors can target the TNF-α molecule (1) or its receptor (2), preventing the resultant signaling pathways. Another target includes TACe (3), which processes the 
26-kDa membrane form of TNF-α to the soluble 17-kDa form preventing its release into the circulation. Inhibition of the activation of NF-κ-B (4) prevents the synthesis of 
NF-κ-B inducible genes, including many pro-inflammatory cytokines. Molecules targeting intracellular TNF-α-related signaling pathways have also been identified, including 
inhibitors of p38 and PDe4 (5).204,205
Abbreviations: cAMP, cyclic AMP; DD, death domain; IB, inhibitor of NF-B; IKK, IB kinase; MeKK1, mitogen-activated protein kinase kinase kinase 1; NF-B, nuclear factor-B; 
NIK, NF-B-inducing kinase; PDe4, phosphodiesterase 4; PKA, protein kinase A; RIP, receptor-interacting protein; TACe, TNF-coverting enzyme; TNF-, tumor-necrosis 
factor-; TNFR1, TNF-receptor 1; TRADD, TNFR1-associated death-domain-containing protein; TRAF2, TNFR-associated factor 2.
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Asymptomatic intra-amniotic infection is confirmed 
when micro-organisms are cultured in amniotic fluid obtained 
during amniocentesis. However, since culture results may 
take several days, measuring pro-inflammatory cytokines in 
amniotic fluid by enzyme-linked immunosorbent assay, as 
markers of intrauterine infection, may provide a quicker way 
of predicting preterm labor. TNFα is not normally detected in 
amniotic fluid in the 2nd and 3rd trimester, but rises during 
normal labor or in pathologic conditions such as intrauterine 
infection.80,93,98 IL-6 present in the amniotic fluid has been 
linked with chorioamnionitis.99 Elevated TNFα . 6.6 pg/mL 
and IL-6 . 99.3 pg/mL levels in amniotic fluid samples 
obtained in asymptomatic women during second trimester 
amniocentesis can identify patients at risk for intra-amniotic 
infection (sensitivity of 78.4% and 91.9% and specificity 
of 70.1% and 73.8%) and preterm delivery (sensitivity of 
81.3% and 89.6% and specificity of 79.2% and 80.3%).37 
However, studies have shown that some patients with a posi-
tive amniotic fluid culture and low levels of pro-inflammatory 
cytokines, still had preterm delivery. This could be due to a 
low maternal response due to functional polymorphism and/
or some bacterial endotoxins may not be potent enough to 
stimulate the pro-inflammatory cytokine response.100
It is still unclear whether cytokines in the maternal 
circulation can predict preterm labor, before symptoms of 
preterm labor or PPROM start. TNFα has been considered as 
a marker of preterm labor, together with other inflammatory 
cytokines such as IL-1B, because it can activate uterotonins 
and increase synthesis of prostaglandins, which can induce 
labor in non-human primates.101–103 A number of studies 
report elevated levels of pro-inflammatory cytokines in mid-
pregnancy amniotic fluid,104 maternal serum and cervical 
samples105,106 among women with preterm delivery, and even 
in placental tissues107–109 of spontaneous preterm deliveries. 
In the Preterm Prediction Study, the use of a combination 
of tests such as maternal serum alpha-fetoprotein, alkaline 
phosphatase, GM-CSF, fetal fibronectin and cervical length 
could enhance prediction of spontaneous preterm birth.110
Cytokines in the circulation are more non-specific than 
amniotic fluid or cervical fluid cytokines, because they 
might reflect a combination of a maternal acute-phase 
response accompanying the local inflammation, together with 
cytokines derived from the feto-placental unit. Therefore, the 
lack of association between preterm and midterm pregnancy 
circulatory cytokine levels in asymptomatic women suggest 
that inflammation occurring in the feto-placental unit may 
not always be reflected in maternal serum levels of TNFα 
and other cytokines. Also, the timing of inflammation in 
pregnancy is probably very important, with inflammation 
occurring in the first trimester having a more significant 
association with adverse pregnancy outcome.111
By contrast, plasma cytokine levels have been mea-
sured in a case-control study among Danish women at 25 
weeks’ gestation, using multiplex flow cytometry (Luminex 
Corporation, Austin, TX). Elevated TNFα levels .75th 
and .90th percentile do not differ by gestational age at 
delivery, and therefore are not associated with an increased 
risk of preterm delivery. There is an increased risk of pre-
term birth with elevated IFNγ and IL-6.112 Therefore, there 
appears to be only limited value in using mid-pregnancy 
cytokines in predicting spontaneous preterm birth. During 
preterm labor, serum levels of IL-6, IL-8 and TNFα are 
not increased when compared to normal control women.113
Bacterial intrauterine infection stimulates maternal 
immune cells to produce pro-inflammatory cytokines.114 In 
non-human primates, inoculation of the amniotic cavity with 
TNFα or IL-1β induces preterm labour.101,115 In mice, TNFα 
causes preterm birth,116 while TNFα-antibodies block LPS-
induced preterm birth.117 Most infections leading to preterm 
birth are subclinical, and it may be possible that women who 
undergo a preterm birth have an increased immune response 
to the causative bacteria. There have been largely conflicting 
results regarding TNFα gene promoter polymorphisms that 
may increase the risk of preterm birth,118 and it is likely that 
either these polymorphisms alone do not cause preterm birth 
in the absence of infection,119 or else these polymorphisms 
do not increase TNFα secretion. Women with a history of 
preterm birth have an elevated TNFα production in response 
to LPS relative to controls.120 However, in another study, 
peripheral blood mononuclear cells from women with a 
history of preterm birth have not produced significantly 
different amounts of TNFα in response to E.Coli, Group B 
Streptococci (S. agalactiae) and U.urealyticum (bacterial 
species causing preterm birth in animal species) compared 
to women with prior uncomplicated term deliveries.121
Cytokine profiles, especially TNFα, differ between 
different ethnic groups and by pregnancy outcome.36,122 In 
pregnancy, the function of TNFα is determined by its spe-
cific binding to one of its two receptors: MMP activation and 
apoptosis through TNFR1 and Nk-kB activation, leading to 
overall enhancement of inflammation through TNFR2.80 The 
soluble forms of these membrane receptors bind to TNFα 
with high affinity and can neutralize TNFα function.95,125–125 
There is a difference in the co-ordination between TNFα 
and its receptors between peoples (African Americans and 
Caucasians) with respect to preterm versus term delivery.
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In Caucasians, midtrimester levels of TNFα and soluble 
TNF-Rs in symptomatic women are not significantly different 
between patients with preterm birth and those who proceed 
to term.36,62 Elevated TNFα concentration in amniotic fluid 
is associated with preterm birth and PPROM,93,94 and the 
bioavailability of TNFα and its receptors influences the 
pathophysiology of these outcomes.95 During an ascending 
infection, the choriodecidua is the first line barrier for 
pathogens such as E.coli, that can cross the amniotic 
membranes and into the amniotic fluid.96 In response to 
this ascending infection, there is abnormal production of 
TNFα in the amnion compartment when the pathogen 
affects both the amniotic membrane and the choriodecidua 
in vitro (comparable to chorioamnionitis in vivo).97
TNFα is produced by both maternal and fetal tissues, 
and increases the production of prostaglandins, myometrial 
activity, induction of MMPs and apoptosis, all of which 
can lead to preterm labor, irrespective of infection.81,93 In 
amniotic membrane samples taken from the placenta of 
Caucasian women, there is a pronounced increase in TNFα 
concentration in response to endotoxin stimulation, com-
pensated by an increase in soluble TNFRs. The latter is not 
evident in African Americans.126 In amniotic fluid taken prior 
to labor (term or preterm) in African Americans (but not in 
Caucasians), there is increased TNFα bioavailability (higher 
TNFα compared to soluble TNFR1 and TNFR2) in women 
who deliver preterm compared to those who deliver at term.36 
Therefore, in Caucasians, but not in African Americans, 
TNFα changes in preterm labor are compensated by changes 
in soluble receptors.36,122
This phenotypic difference of African Americans having 
a significant cytokine imbalance is caused by variation in the 
genes encoding these proteins, with significant differences 
between allelic, genotypic and haplotypic frequency differ-
ences in TNFα and TNFα receptor genes between different 
peoples.118,127 However, no association has been observed 
between these single nucleotide polymorphisms, including the 
TNFα promoter functional variant (-308) and other markers in 
the TNFα and TNFα receptor genes, and preterm birth.127 This 
may be due to gene-environment interactions, with the effects 
of some single nucleotide proteins differing as a function of 
specific environmental factors. The presence of the TNFα 
risk allele at -308 can modify pregnancy outcome through 
interactions with bacterial vaginosis and periodontitis, even 
in the absence of an independent single locus effect.98,119,128 
Therefore, genetic regulation of TNFα and soluble TNF-Rs 
concentrations in amniotic fluid is affected by ethnicity and 
preterm birth.34 In Caucasians, TNF-Rs in the amniotic fluid 
are higher in preterm than in term patients; but in African 
Americans, amniotic fluid TNF-Rs are higher in term versus 
preterm patients.34 The disparity in inflammatory cytokine 
profiles found in amniotic fluid can partly explain the higher 
rate of preterm birth among African Americans and Cauca-
sians in the United States. In African Americans with term 
birth, TNFα and IL-10 concentrations in amniotic fluid are 
positively correlated, indicating a generalized inflammatory 
status during labor, but there is a negative correlation coeffi-
cient in preterm birth with an overwhelming increase in TNFα 
not being co-ordinated by IL-6.129 In this ethnic group, preterm 
labor is mediated predominantly by TNFα and IL-1β.101 IL-10 
levels correlated with soluble TNFR1 and TNFR2 in preterm, 
confirming immunoinhibitory mechanisms during preterm 
labor, which are overwhelmed by the increase in TNFα and 
IL-1. Therefore, the pathways leading to preterm birth may 
be different in the two ethnic groups.130
There are probably other unmeasured (environmental) 
factors that interact to alter cytokine levels in amniotic 
fluid. Women with bacterial vaginosis and TNFα promoter 
polymorphism (-G238A) are at increased risk of delivering 
preterm, irrespective of ethnicity,131 further illustrating a 
potential gene-environment interaction in preterm delivery. 
The presence of bacterial vaginosis is associated with  elevated 
levels of TNFα and other pro-inflammatory cytokines, such 
as IL-1, in the vaginal fluid.132,133 In vitro experiments 
with decidual and amniotic cells, these pro-inflammatory 
cytokines are able to induce the release of prostaglandins and 
MMPs.134,135 Therefore, high levels of TNFα in the presence 
of bacterial vaginosis may stimulate contractions and/or 
degradation of membranes.
It has been shown that during maternal infection, TNFα 
and IFNγ increase the production of prostaglandins, resulting 
in premature labor.136,137 A positive association has been shown 
between elevated levels of pro-inflammatory cytokines, includ-
ing TNFα, IFNγ, IL-1, and IL-8.138–140 Studies have shown 
conflicting evidence as to whether increasing levels of TNFα 
are associated with an increased risk of intra-uterine growth 
restriction.141–143 In a recent study, higher levels of TNFα in 
umbilical cord blood was associated with preterm delivery, but 
not with intra-uterine growth restriction.144 Interestingly, higher 
levels of other pro-inflammatory markers in the umbilical cord 
blood, such as IFNγ and interleukin 12p70, are associated with 
decreased risk of small for gestational age.144
TNFα and preeclampsia
Preeclampsia is a potentially life-threatening complex 
multisystem maternal disorder that can occur in the second 
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half of pregnancy, labor or the early postpartum period. 
It is characterized by high blood pressure, proteinuria and 
other systemic disturbances secondary to diffuse maternal 
endothelial dysfunction.145 Preeclampsia is considered as a 
state of exaggerated inflammation, in excess of the baseline 
inflammatory state of normal pregnancy, with local and 
systemic changes in Th1/Th2 cytokines.146 Polymorphisms 
of cytokine genes may increase the risk of developing 
preeclampsia.147 Peripheral blood mononuclear cells and 
decidual lymphocytes express higher levels of Th1 cytokines, 
including TNFα, and lower Th2 cytokine expression in 
preeclampsia compared to normal pregnancy.148,149 This is 
reflected in the maternal circulation, with a further rise in 
pro-inflammatory cytokines such as TNFα, accompanied 
by an elevated level of soluble receptor in an attempt to 
dampen the cytokine response.150–153 Increased levels of 
TNFα and other pro-inflammatory cytokines have also been 
found in the umbilical serum of pregnancies complicated 
by preeclampsia, suggesting a role in intra-uterine growth 
restriction secondary to preeclampsia.154 The rise in pro-
inflammatory cytokine TNFα and TNF-R1 in maternal 
circulation increases as early as 11–13 weeks, well before 
the clinical manifestation of preeclampsia,155 but so far has 
not proved to be useful in screening.156
In placental preeclampsia, there is defective placentation 
with insufficient remodeling of the uterine spiral arteries 
by the EVT towards the end of the first trimester and in the 
early second trimester leading to an ischemia-reperfusion 
phenomenon with subsequent excessive oxidative stress.157 
It has been shown that placentation is better, with a decrease 
in incidence of preeclampsia, if the trophoblast strongly 
stimulates maternal uterine NK cells, which in turn secrete 
pro-inflammatory cytokines to allow proper invasion.158 
Activity of decidual NK cells is in turn regulated by a 
complex network of cytokines.159 Pro-inflammatory cytokines 
such as IL-1 can stimulate MMP-9 and 2160 and therefore 
can act as positive regulators of trophoblast differentiation 
in becoming more invasive. The contrary has been shown for 
anti-inflammatory cytokines such as IL-10 and transforming 
growth factor β.161,162 As mentioned above, there is a 
predominance of TNFα in cell columns during invasion, 
especially in the EVT, as it displaces the endothelial cells of 
the spiral arteries.46,47
TNFα and its receptors are expressed in excess 
both systemically and at the feto-maternal interface146 
and may play a key role in the pathophysiology of 
preeclampsia. In preeclampsia, TNFα, together with IFNγ, 
has been shown to cause apoptosis of cultured cytoblasts 
and syncytiotrophoblasts, together with impairment of 
syncytialization, especially under hypoxic conditions in term 
placenta.163 In vitro studies have shown that the combination 
of TNFα and IFNγ inhibit first trimester EVT invasion 
due to increased apoptosis and reduced proliferation of 
EVT cells and reduced pro-MMP-2 secretion.164 Hypoxia/
re-oxygenation leading to placental oxidative stress is a 
potent inducer of TNFα secretion by villous explants.73 
Since there is an elevation of both of these pro-inflammatory 
cytokines in the placenta of preeclamptic patients,165,166 
they may have a role in abnormal placentation. TNFα may 
inhibit migration of EVT in the first trimester placenta via 
elevated plasminogen activator inhibitor-1167 or via activated 
macrophages.168 The sources of TNFα in preeclampsia are the 
trophoblast cells themselves due to the ischemia-reperfusion 
insult,56,169 as well as the activated maternal monocytes upon 
adhering to the syncytiotrophoblast.170,171 TNFα has also 
been shown to inhibit the subset of CD4+CD25+ regulatory 
T lymphocytes.172 The latter cells promote fetal tolerance 
during normal pregnancy, and once inhibited, will not be able 
to produce immunosuppressive cytokines that are important 
at the feto-placental interface to prevent fetal rejection.173
Preeclampsia is associated with a systemic inflammatory 
response, which is more exaggerated than what happens in 
normal pregnancy, due to aberrant cytokine expression.174 
In early onset preeclampsia, TNFα/IL-10 findings suggest 
that an imbalance in pro-inflammatory to anti-inflammatory 
cytokines ratio is associated with unfavorable pregnancy 
outcomes.175 Toll-like receptor (TLR)-4 increases production 
of TNFα.176 TLR is the main danger signaling pathway 
involved in the pathogenesis of preeclampsia.177 TLR2 and 
TLR4 single nucleotide proteins appear to alter the maternal 
susceptibility to preeclampsia.178
TNFα is a potential mediator of endothelial cell dysfunc-
tion, contributing to the systemic effects of preeclampsia.150,179 
The excess TNFα produced by the placental villous tissue 
in response to the hypoxia-reperfusion injury affects the 
 endothelial cells by reducing their viability, and upregu-
lating the expression of adhesion molecule E-selectin.56 
Excess placental production of factors, such as vascular 
endothelial growth factor receptor-1 (also known as soluble 
fms-like tyrosine kinase 1 (sFlt-1)), which bind to vascular 
endothelial growth factor and placental growth factor are 
anti-angiogenic.180,181 They deprive the systemic endothelium 
of essential survival factors, decreasing the number of 
adhesion complexes at the cytoplasmic membrane, leading 
to vascular permeability.182 However, the role of cytokines 
to this particular endothelial response to serum factors 
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is still not clear. Elevated angiotensin II type-1 receptor 
autoantibodies (AT1-AA), together with cytokines, lead to 
dysfunctional maternal vascular endothelium.183 This in turn 
leads to increased levels of circulating endothelin, reactive 
oxygen species, and increased vascular sensitivity to angio-
tensin II, together with lower levels of vasodilators, such as 
prostacyclin and nitric oxide.184 This can lead to multi-organ 
dysfunction in preeclampsia, including hemolysis, elevated 
liver enzymes and low platelets syndrome.184,185 Sex steroids 
also play a role in modulating the effect of TNFα on vascular 
function in preeclampsia. However, in rats, increased levels 
of ovarian hormones to those observed in pregnancy were 
not sufficient to induce TNFα-induced vascular changes 
observed in preeclampsia.186 Trophoblastic debris, including 
syncytiotrophoblast membrane microparticles, fetal soluble 
RNA and DNA, cytokeratin fragments and cytotrophoblast 
cells, is released into the maternal circulation by apoptotic and 
necrotic processes in elevated amounts compared to normal 
pregnancy. This debris is pro-inflammatory and, through 
the release of cytokines such as TNFα, aggravates maternal 
inflammation.187 It has been shown that placental ischemia 
leading to preeclampsia is associated with raised inflammatory 
cytokines such as TNF α, and CD4+ T helper cells.188
Currently, there is no reliable test that can be used for 
screening or to facilitate informed decision during manage-
ment of preeclampsia. Therefore, better understanding of 
the link between abnormal hemostasis and inflammation in 
preeclampsia may clarify the underlying pathophysiology, 
and help design primary preventative and therapeutic mea-
sures at an early stage.189
TNFα-inhibitors and their role  
in pregnancy
Over the past 2 decades, anti-TNFα treatment has been 
developed, including etanercept (Enbrel), a recombinant 
soluble TNF-R2, and monoclonal TNFα-antibodies, such 
as adalimumab (Humira), infliximab (Remicode) and cer-
tolizumab pegol (Cimzia). These have been licensed for use 
in the treatment of autoimmune diseases such as inflam-
matory arthritis190 and inflammatory bowel disease,191 and 
there is also research showing their possible role in the 
management of recurrent colorectal cancer.192 Because of the 
immuno-modulatory action of these biologicals, there have 
been associated increased risks of infections such as viral, 
tuberculosis and histoplasmosis, and lymphoma.193
In an LPS-induced murine model of preterm birth, the 
use of anti-TNFα treatment decreased fetal deaths and pre-
term deliveries.117 Although regulatory agencies encourage 
the participation of pregnant and breastfeeding women in 
randomized controlled trials, this subset of the population 
has universally been excluded from studies involving the 
use of anti-TNFα treatment because of unknown or potential 
risks to the fetus. Thus, strong evidence-based treatment 
recommendations during pregnancy is lacking, and TNFα 
inhibitors are listed as Class B, that is, animal reproduction 
studies have failed to demonstrate fetal risk and there are no 
well-controlled studies in pregnant women.
Since autoimmune diseases such as Crohn’s disease, 
ulcerative colitis, and rheumatoid, psoriatic, and juvenile 
idiopathic arthritis are prevalent in women of childbearing 
age, there have been a number of case reports and registries 
documenting the effect of the incidental use of anti-TNFα 
agents in women who inadvertently became pregnant while 
on treatment.194–196 Overall, conflicting results have been 
produced from these case reports and small case series, 
partly due to the different timing of when the treatment was 
taken, other concurrent medication such as methotraxate, 
and different underlying autoimmune conditions of vary-
ing severity. Occurrence of uncommon adverse pregnancy 
outcomes observed with TNFα inhibitor therapy, such as 
premature birth, miscarriage, low birth weight, hyperten-
sion, and preeclampsia appear to approximate those seen 
in women not receiving such therapy and may be due to the 
underlying autoimmune condition itself.197 While there is data 
suggesting little to no risk of congenital anomalies,197 a large 
independent review of the Food and Drug Administration 
database reports a higher number of VACTERL anomalies 
in offspring of mothers who were on TNFα-antagonists at 
some point during their pregnancy.198,199
VACTERL is a non-random association of birth defects, 
including vertebral anomalies (V), anal atresia (A), car-
diovascular anomalies (C), tracheoesophageal fistula (T), 
esophageal atresia (E), renal and/or radial anomalies (R) 
and limb defects (L). So far, the recommendations per obser-
vational studies are that women of childbearing age with 
autoimmune diseases should ideally plan to conceive when 
their disease is well controlled and while on no medication, 
and most pregnant patients can discontinue their anti-TNFα 
treatment early in pregnancy without increasing maternal 
and fetal risks.197
Anti-TNFα treatment has been shown to increase live 
birth rates in women with recurrent spontaneous abortion67 
and in a subset of patients with a history of .2 failed in-vitro 
fertilization attempts,200 with the latter study having an 
impressive 100% pregnancy and 88% take-home baby rate. 
In both of the cohort-controlled, non-randomized studies, 
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treatment was generally started a month prior to starting a 
cycle of conception, and continued until a fetal heart was 
demonstrable by ultrasound. Minimal side-effects and no 
birth defects were reported. Pretreatment with anti-TNFα 
is thought to reduce Th1/Th2 levels in CD3+ cells by 
upregulating regulatory T-cell activity in women with Th1 
driven inflammation.201 However, in both studies there could 
have been a selection bias in the choice of patients, because 
many of the patients without anti-TNFα treatment lacked 
the high qualifying ratio of Th1/Th2. The karyotype was not 
tested in the cases of recurrent miscarriage, and the maternal-
fetal genotype was unknown. There are also other factors 
controlling reproductive outcome, such as autoantibodies 
and coagulation defects, therefore using Th1/Th2 ratios 
alone may not be enough to determine who would benefit 
from anti-TNFα treatment. Also, one needs to define at what 
level is Th1/Th2 ratio considered high to merit a beneficial 
effect from anti-TNFα treatment.
Although the observational studies of Winger et al 
represent important new data in the field of reproductive 
immunology,67,200,202,203 further prospective randomized 
controlled studies are needed. Studies in mice are showing 
that targeting placental TNFα using TNFα-antagonists such 
as etanercept prevents fetal hypoxia and neuroproliferative 
defects in the fetal brain.70 Understanding the mechanism of 
action of TNFα and its receptors may lead to development of 
new drugs to decrease the pro-inflammatory effects of this 
cytokine (Figure 1).
Conclusion
There is still a lot to be learnt about the role of TNF-R1 and 
TNF-R2 in normal and complicated pregnancies. Recently, 
studies have shown that altered levels of these receptors in 
the circulation, in combination with other cytokines and/
or hormones, may play a role in predicting miscarriage in 
patients presenting with threatened miscarriage.206 Future 
clinical trials are needed to study the possible benefit of 
anti-TNF treatment in pregnancy complications.
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